Egrifta (Tesamorelin) FAERS Safety Signals: What the Post-Market Data Actually Show

What Is Tesamorelin and Why Does Its Post-Market Safety Profile Matter?

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). Unlike recombinant human growth hormone (rhGH), it stimulates the pituitary to release growth hormone in a pulsatile, physiologically regulated pattern rather than delivering a supraphysiologic bolus. That distinction shapes its safety profile significantly. The FDA granted approval on November 10, 2010 under NDA 022505, making Egrifta the first and only drug approved specifically for HIV-associated lipodystrophy. [1]

Post-market surveillance matters here for a specific reason: the key trials enrolled a relatively narrow population, HIV-infected adults on stable antiretroviral therapy, over 26-week windows. Real-world patients often differ in age, comorbidities, and concomitant medications. FAERS captures those deviations.

The FAERS Database: How It Works for Tesamorelin

The FDA Adverse Event Reporting System (FAERS) is a spontaneous reporting database. Reports come from manufacturers (who are legally required to submit), healthcare providers, and patients. Because reporting is voluntary for non-manufacturers, FAERS is subject to underreporting bias, and signal detection does not establish causation. The FDA uses disproportionality statistics, primarily the Reporting Odds Ratio (ROR) and Information Component (IC), to identify signals that appear more frequently than background noise. [2]

For tesamorelin, the FAERS Public Dashboard shows cumulative reports dating from the 2010 approval period. The most commonly reported preferred terms cluster around the drug's known pharmacology: IGF-1 increase, peripheral edema, arthralgia, and injection-site reactions. [2]

Regulatory Timeline: Key Dates Clinicians Should Know

• November 2010: FDA approves NDA 022505 for Egrifta 2 mg/day. [1]
• 2014: Theratechnologies receives FDA approval for Egrifta SV (a second-generation, single-vial formulation) under NDA 210822, preserving the same indication and dose. [3]
• Ongoing: Manufacturer is required to submit periodic adverse drug experience reports (PADERs) and any 15-day alert reports for unexpected serious adverse events to FDA under 21 CFR 314.81. [4]

The Current Egrifta Prescribing Label: Signal-by-Signal Breakdown

The FDA-approved full prescribing information for tesamorelin is the most authoritative source for known safety signals. Every signal listed has regulatory backing from either the key trials, post-market reports, or both. [5]

Fluid Retention and Musculoskeletal Adverse Effects

Growth hormone drives sodium and water retention via the renin-angiotensin-aldosterone system. Tesamorelin's stimulation of endogenous GH carries that same liability. In the pooled Phase 3 data reviewed for the NDA, peripheral edema occurred in 6.3% of tesamorelin-treated patients versus 2.6% on placebo. Arthralgia was reported in 12.7% versus 7.9%, and myalgia in 5.9% versus 3.6%. [5]

Carpal tunnel syndrome, another GH-class effect, appeared at a lower rate but is listed in the label. Clinicians should ask patients about hand numbness or tingling at every follow-up visit. [5]

Glucose Metabolism and Diabetes Risk

Tesamorelin raises IGF-1, which has insulin-sensitizing properties at the receptor level, but GH itself is counter-regulatory and can impair insulin secretion and increase insulin resistance. The net effect in clinical trials was a small but measurable increase in fasting glucose and HbA1c compared to placebo. [6]

In the Falutz et al. NEJM 2007 trial (N=412 across two controlled studies), glucose metabolism changes were modest and did not reach the threshold for new diabetes diagnoses in most patients, but the label now requires monitoring of fasting glucose at baseline and periodically, with particular attention in patients who are pre-diabetic or already on insulin. [6] The FDA label states explicitly: "Tesamorelin may cause glucose intolerance. Physicians should weigh the risks and benefits of Egrifta treatment in patients with diabetes or at risk for diabetes." [5]

IGF-1 Elevation: The Surrogate Signal Worth Watching

IGF-1 is both a pharmacodynamic marker and a safety concern. Supraphysiologic IGF-1 is associated with increased cancer risk in epidemiological cohorts, though no causal link between tesamorelin treatment and malignancy has been established in randomized data to date. The label requires baseline IGF-1 measurement and periodic monitoring. If IGF-1 levels rise above age- and sex-normalized reference ranges on two consecutive measurements, the label guidance supports dose adjustment or discontinuation. [5]

The FDA's pharmacovigilance review for tesamorelin specifically flagged IGF-1 elevation as a signal requiring long-term follow-up, a requirement that was incorporated as a post-marketing commitment in the original approval package. [1]

FAERS Signal Analysis: What Spontaneous Reports Add to the Label

Spontaneous FAERS data extend the label by capturing signals that emerge in broader, more diverse populations over longer time horizons. For tesamorelin, several patterns are worth examining.

Injection-Site Reactions: The Highest-Volume Signal

Injection-site reactions, including erythema, pruritus, pain, and induration, consistently represent the largest category of FAERS reports for tesamorelin. This is consistent with the label (injection-site erythema: 8.8% tesamorelin vs. 4.1% placebo in pooled trials) and with the drug's daily subcutaneous dosing regimen. [5]

Proper injection technique, site rotation across the abdomen, and avoiding areas of lipodystrophic tissue can reduce reaction frequency. The FDA's medication guide for Egrifta, available on the accessdata.fda.gov label page, includes illustrated rotation diagrams. [3]

Neoplasm-Related Reports: Low Absolute Numbers, Regulatory Attention

One of the more closely watched FAERS signal categories for any GH-axis drug is neoplasm. Because GH and IGF-1 are mitogenic, the theoretical concern about cancer promotion is built into every GHRH analogue's regulatory dossier. For tesamorelin, the label carries a contraindication in patients with active malignancy and states the drug should be discontinued if malignancy is diagnosed during treatment. [5]

Spontaneous FAERS reports of neoplasm in tesamorelin-treated patients exist, but the disproportionality statistics have not risen to the level of a formal FDA safety communication as of the most recent FAERS quarterly update. The FDA's Sentinel System, which uses insurance claims and electronic health record data from more than 100 million patients, provides a more statistically powered post-market tool. [7] Sentinel analyses for GH-axis drugs have not produced a confirmed neoplasm signal for tesamorelin specifically, though the surveillance continues. [7]

Cardiovascular Signals in an HIV Population

HIV-infected patients on antiretroviral therapy carry an elevated baseline cardiovascular risk independent of any drug effect. That confounding makes it difficult to attribute FAERS cardiovascular reports specifically to tesamorelin. However, because GH can promote fluid retention and may affect lipid metabolism, the FDA required cardiovascular monitoring be discussed in the label. [5]

Paradoxically, the drug's approved indication of reducing visceral adiposity is itself cardiovascular risk-modifying, as excess visceral fat is an independent predictor of cardiovascular events. A 2014 analysis published in the Journal of Clinical Endocrinology and Metabolism found that tesamorelin-treated patients showed significant reductions in triglycerides alongside visceral fat loss, a potentially favorable cardiovascular signal. [8]

How the Key Trial Safety Data Anchor the FAERS Interpretation

The Falutz et al. 2007 NEJM trial remains the foundational safety reference for tesamorelin. [6] Two parallel randomized, double-blind, placebo-controlled trials enrolled 412 HIV-infected adults with abdominal fat accumulation. Patients received tesamorelin 2 mg/day or placebo for 26 weeks. Key safety findings from that dataset include the following.

Adverse Event Rates From the Phase 3 Data

Across the two trials, the most common treatment-emergent adverse events in the tesamorelin group included peripheral edema (6.3%), arthralgia (12.7%), myalgia (5.9%), nausea (5.9%), and injection-site erythema (8.8%), all at higher rates than placebo. [6] Mean IGF-1 SDS (standard deviation score) increased from approximately 0 at baseline to +1.7 at week 26 in the tesamorelin arm, remaining within the age-adjusted normal range for most but not all participants. [6]

The trial did not show statistically significant differences in serious adverse event rates between groups, with serious adverse events occurring in 10.1% of tesamorelin patients and 11.6% of placebo patients. P values for this comparison were not significant. [6]

Extension Data: Safety Beyond 26 Weeks

A 26-week extension phase (total 52 weeks) was reported by Falutz et al. In subsequent publications and incorporated into the FDA review. Safety signals did not intensify meaningfully over the extended period. Patients re-randomized from tesamorelin to placebo showed rapid reversal of visceral fat reduction, confirming that the drug effect is maintenance-dependent. [9] Clinically, this means patients who discontinue tesamorelin should be counseled to expect visceral fat accumulation to resume, not that a new safety event is occurring.

Pediatric and Pregnancy Exclusions

Tesamorelin's approval explicitly excludes use in pediatric patients. Because GHRH stimulation in open-growth-plate patients carries bone maturation risk, and because no pediatric trials were conducted, the label states the drug is not approved for use in patients under 18. [5] Pregnancy is an absolute contraindication, given tesamorelin's FDA Pregnancy Category X designation, and animal studies showed fetal harm at doses below the human therapeutic range. [5]

Comparing Tesamorelin's Safety Profile to rhGH: A Regulatory Perspective

Recombinant human growth hormone (e.g., somatropin) carries a longer, more densely populated FAERS database simply because it has been on the market since 1985 and has broader approved indications. [10] Comparing the two is instructive.

RhGH delivers fixed exogenous GH, bypassing pituitary feedback. Tesamorelin, by contrast, stimulates endogenous pulsatile GH release, which means the pituitary's somatostatin-mediated negative feedback remains active. This pharmacological difference appears to translate into a lower incidence of IGF-1 supranormality, at least in the controlled trial data. [6] The FDA's risk evaluation for NDA 022505 specifically cited this mechanistic distinction as a factor in the benefit-risk determination. [1]

Both drug classes share the class-effect warnings around glucose intolerance, fluid retention, and theoretical neoplasm promotion. Any clinician managing a tesamorelin patient who has experience with rhGH should not assume tesamorelin is entirely risk-free on these dimensions.

FDA Post-Market Commitments and Ongoing Surveillance Requirements

At the time of the 2010 approval, the FDA required Theratechnologies to fulfill several post-marketing study commitments. These included a cardiovascular outcomes study in the HIV-lipodystrophy population and long-term IGF-1 surveillance data. [1] The status of these commitments is tracked on the FDA's post-market studies database, updated annually. [11]

What Sentinel Adds to FAERS for Tesamorelin

The FDA's Sentinel System differs from FAERS in one critical way: it uses structured electronic health record and claims data, giving it the statistical power to detect signals that spontaneous reporting misses. Sentinel has published methods papers establishing its approach to GH-axis drug monitoring. [7] For tesamorelin, Sentinel's active surveillance provides a check on the raw FAERS signal counts.

Clinicians who want to track regulatory updates on tesamorelin can monitor the FDA's Drug Safety Communications page and the accessdata.fda.gov label repository, where label revisions are time-stamped and searchable. [3]

15-Day Alert Reports and Label Changes Since 2010

Under 21 CFR 314.80, manufacturers must submit expedited 15-day safety reports for unexpected serious adverse drug reactions. Theratechnologies has submitted periodic updates consistent with these requirements. [4] The label has undergone revisions since 2010, including the introduction of the Egrifta SV formulation label in 2014. Current prescribing information is accessible at the FDA's accessdata portal. [3]

Practical Safety Monitoring: A Clinical Framework for Tesamorelin Prescribers

Managing tesamorelin safely requires a structured baseline and follow-up protocol grounded in both the label and the post-market evidence.

Baseline Assessment Checklist

Before initiating tesamorelin 2 mg/day subcutaneously, clinicians should confirm the following.

• Active malignancy ruled out (contraindication per label). [5]
• Pregnancy test negative in women of reproductive potential (Category X). [5]
• Fasting glucose and HbA1c measured. [5]
• IGF-1 measured with age- and sex-specific normative reference. [5]
• Pituitary or hypothalamic disease excluded (disrupts endogenous GHRH axis). [5]
• Antiretroviral regimen stable for at least 8 weeks before starting tesamorelin. [5]

Monitoring Schedule During Treatment

The FDA label and the clinical trial protocols support the following monitoring cadence.

• At 3 months: Repeat fasting glucose, IGF-1, and symptom review for edema, arthralgia, and carpal tunnel symptoms. [5]
• At 6 months: Repeat all the above plus a visceral fat assessment (waist circumference or DEXA-based VAT quantification if available) to confirm treatment response. [6]
• Annually: Full metabolic panel, IGF-1, and HbA1c. Consider DEXA if clinical benefit is uncertain. [5]

If IGF-1 exceeds the upper limit of normal on two consecutive measurements taken at least four weeks apart, dose reduction or temporary discontinuation is warranted. [5] The Endocrine Society's clinical practice guidelines on adult GH deficiency, which address IGF-1 monitoring principles applicable across GH-axis therapies, recommend targeting the middle tertile of the age-adjusted normal range. [12]

Regulatory Comparison: EMA Perspective on Tesamorelin

Tesamorelin is not approved by the European Medicines Agency. The EMA does not have a current marketing authorization for Egrifta, and no EPAR (European Public Assessment Report) exists for tesamorelin as of 2025. This regulatory gap means European post-market data do not contribute to the global pharmacovigilance dataset at the same level as the US FAERS data. Clinicians outside the US who prescribe tesamorelin through compassionate use or importation programs should be aware that the only formal regulatory safety dossier remains the FDA NDA 022505 package. [1]

The absence of EMA approval also means European Sentinel-equivalent systems, such as EMA's EudraVigilance database, contain minimal tesamorelin reports. [13] The FDA FAERS database is therefore the primary global pharmacovigilance source for this drug.

What Patients Should Know About FAERS Reports

FAERS reports represent real patient experiences, but they require context. A report in FAERS does not mean the drug caused the event. HIV-infected patients on antiretroviral therapy have high background rates of metabolic disorders, cardiovascular events, and glucose dysregulation independent of any lipodystrophy treatment. Disentangling drug-attributable risk from disease-attributable risk requires the kind of controlled analysis that FAERS alone cannot provide. [2]

That context matters when patients ask about FAERS search results. A practical approach is to walk patients through the label-listed adverse event rates from the key trials, which provide denominator data that FAERS lacks, and then explain that the spontaneous reports largely mirror those known signals without introducing new, unexpected safety concerns at rates that have triggered formal FDA safety communications.

Patients should also know that new safety information, if discovered, would appear first as a Drug Safety Communication on the FDA website before being incorporated into the label. [14] Subscribing to FDA MedWatch alerts for tesamorelin is a practical step for both clinicians and engaged patients. [14]